Literature DB >> 1464346

The potential role of endothelin as a vasoconstrictor substance in congestive heart failure.

R J Cody1.   

Abstract

A rapidly growing body of data supports the concept of in situ regulation of vascular tone: the ability of vasoactive substances to regulate vascular tone at their site of production within the wall of the vasculature. Sufficient data exist to suggest that ineffective production or response to endothelium-dependent vasodilator substances, or excessive production or responsiveness to endothelium-dependent vasoconstrictor substances may play an important role in cardiovascular disorders such as hypertension, coronary artery spasm, restenosis following coronary angioplasty, and congestive heart failure. The present review summarizes data which support the concept that endothelin, a potent vasoconstrictor produced by the endothelium, may play a role in the excessive vasoconstriction of heart failure. Increased circulating plasma endothelin may be particularly relevant to the range of pulmonary vasoconstriction encountered in congestive heart failure, with a correlation revealing that the greatest increase of plasma endothelin occurs in patients with marked pulmonary hypertension within the congestive heart failure patients studied.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1464346     DOI: 10.1093/oxfordjournals.eurheartj.a060103

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  3 in total

1.  Role of endogenous endothelin in the regulation of basal coronary tone in the rat.

Authors:  A T Goodwin; M Amrani; C C Gray; J Jayakumar; M H Yacoub
Journal:  J Physiol       Date:  1998-09-01       Impact factor: 5.182

Review 2.  Neuroendocrine changes in chronic cardiac failure.

Authors:  D P Nicholls; G N Onuoha; G McDowell; J S Elborn; M S Riley; A M Nugent; I C Steele; C Shaw; K D Buchanan
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

3.  Spasms of the hepatic artery following percutaneous transluminal angioplasty and tolazoline administration in a liver transplant patient.

Authors:  A Propst; P Waldenberger; T Propst; W Vogel; A Königsrainer; A K Jaschke
Journal:  Cardiovasc Intervent Radiol       Date:  1996 May-Jun       Impact factor: 2.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.